Clinical Trial Update: Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a novel neoadjuvant and adjuvant strategy for patients with germline BRCA1/2-mutated triple-negative breast cancer. Recruitmen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Snippet

Sponsor: Okayama University | Conditions: Triple Negative Breast Neoplasms, Triple Negative Breast Cancer | Phase 2 | Status: RECRUITING